218 related articles for article (PubMed ID: 29968534)
1. Verification between Original and Biosimilar Therapeutic Antibody Infliximab Using nSMOL Coupled LC-MS Bioanalysis in Human Serum.
Iwamoto N; Yokoyama K; Takanashi M; Yonezawa A; Matsubara K; Shimada T
Curr Pharm Biotechnol; 2018; 19(6):495-505. PubMed ID: 29968534
[TBL] [Abstract][Full Text] [Related]
2. Multiplexed monitoring of therapeutic antibodies for inflammatory diseases using Fab-selective proteolysis nSMOL coupled with LC-MS.
Iwamoto N; Takanashi M; Yokoyama K; Yonezawa A; Denda M; Hashimoto M; Tanaka M; Ito H; Matsuura M; Yamamoto S; Honzawa Y; Matsubara K; Shimada T
J Immunol Methods; 2019 Sep; 472():44-54. PubMed ID: 31201793
[TBL] [Abstract][Full Text] [Related]
3. Application of nSMOL coupled with LC-MS bioanalysis for monitoring the Fc-fusion biopharmaceuticals Etanercept and Abatacept in human serum.
Iwamoto N; Yokoyama K; Takanashi M; Yonezawa A; Matsubara K; Shimada T
Pharmacol Res Perspect; 2018 Jul; 6(4):e00422. PubMed ID: 30062014
[TBL] [Abstract][Full Text] [Related]
4. Validated LC-MS/MS analysis of immune checkpoint inhibitor Nivolumab in human plasma using a Fab peptide-selective quantitation method: nano-surface and molecular-orientation limited (nSMOL) proteolysis.
Iwamoto N; Shimada T; Terakado H; Hamada A
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Jun; 1023-1024():9-16. PubMed ID: 27155936
[TBL] [Abstract][Full Text] [Related]
5. Infliximab quantitation in human plasma by liquid chromatography-tandem mass spectrometry: towards a standardization of the methods?
Jourdil JF; Lebert D; Gautier-Veyret E; Lemaitre F; Bonaz B; Picard G; Tonini J; Stanke-Labesque F
Anal Bioanal Chem; 2017 Feb; 409(5):1195-1205. PubMed ID: 27826630
[TBL] [Abstract][Full Text] [Related]
6. Acceleration of nano-surface and molecular-orientation limited (nSMOL) proteolysis with acidified reduction pretreatment for quantification of Tocilizumab.
Iwamoto N; Yonezawa A; Matsubara K; Shimada T
J Pharm Biomed Anal; 2019 Feb; 164():467-474. PubMed ID: 30447535
[TBL] [Abstract][Full Text] [Related]
7. Quantification of active infliximab in human serum with liquid chromatography-tandem mass spectrometry using a tumor necrosis factor alpha -based pre-analytical sample purification and a stable isotopic labeled infliximab bio-similar as internal standard: A target-based, sensitive and cost-effective method.
El Amrani M; van den Broek MP; Göbel C; van Maarseveen EM
J Chromatogr A; 2016 Jul; 1454():42-8. PubMed ID: 27264745
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous Quantification of Adalimumab and Infliximab in Human Plasma by Liquid Chromatography-Tandem Mass Spectrometry.
Jourdil JF; Némoz B; Gautier-Veyret E; Romero C; Stanke-Labesque F
Ther Drug Monit; 2018 Aug; 40(4):417-424. PubMed ID: 29608486
[TBL] [Abstract][Full Text] [Related]
9. Regulated LC-MS/MS bioanalysis technology for therapeutic antibodies and Fc-fusion proteins using structure-indicated approach.
Iwamoto N; Shimada T
Drug Metab Pharmacokinet; 2019 Feb; 34(1):19-24. PubMed ID: 30392772
[TBL] [Abstract][Full Text] [Related]
10. Antibody drug quantitation in coexistence with anti-drug antibodies on nSMOL bioanalysis.
Iwamoto N; Hamada A; Shimada T
Anal Biochem; 2018 Jan; 540-541():30-37. PubMed ID: 29128290
[TBL] [Abstract][Full Text] [Related]
11. Validated LC/MS Bioanalysis of Rituximab CDR Peptides Using Nano-surface and Molecular-Orientation Limited (nSMOL) Proteolysis.
Iwamoto N; Takanashi M; Hamada A; Shimada T
Biol Pharm Bull; 2016 Jul; 39(7):1187-94. PubMed ID: 27150271
[TBL] [Abstract][Full Text] [Related]
12. Application of nano-surface and molecular-orientation limited proteolysis to LC-MS bioanalysis of cetuximab.
Iwamoto N; Takanashi M; Umino Y; Aoki C; Hamada A; Shimada T
Bioanalysis; 2016 May; 8(10):1009-20. PubMed ID: 26972866
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Infliximab and Anti-infliximab LISA-TRACKER Immunoassays for the Therapeutic Drug Monitoring of SB2 Infliximab Biosimilar.
Jentzer A; Berger AE; Labetoulle R; Haccourt A; Roblin X; Paul S
Ther Drug Monit; 2018 Dec; 40(6):749-753. PubMed ID: 30439790
[TBL] [Abstract][Full Text] [Related]
14. Fully validated LCMS bioanalysis of Bevacizumab in human plasma using nano-surface and molecular-orientation limited (nSMOL) proteolysis.
Iwamoto N; Umino Y; Aoki C; Yamane N; Hamada A; Shimada T
Drug Metab Pharmacokinet; 2016 Feb; 31(1):46-50. PubMed ID: 26830079
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous Quantification of Free Adalimumab and Infliximab in Human Plasma Using a Target-Based Sample Purification and Liquid Chromatography-Tandem Mass Spectrometry.
El Amrani M; Bosman SM; Egas AC; Hack CE; Huitema ADR; van Maarseveen EM
Ther Drug Monit; 2019 Oct; 41(5):640-647. PubMed ID: 31584927
[TBL] [Abstract][Full Text] [Related]
16. Analytical and clinical performance evaluation of two POC tests for therapeutic drug monitoring of infliximab.
Van den Bossche D; De Smet D; Debrabandere J; Vanpoucke H
Clin Chem Lab Med; 2019 May; 57(6):856-863. PubMed ID: 30838834
[TBL] [Abstract][Full Text] [Related]
17. LC-MS bioanalysis of Trastuzumab and released emtansine using nano-surface and molecular-orientation limited (nSMOL) proteolysis and liquid-liquid partition in plasma of Trastuzumab emtansine-treated breast cancer patients.
Iwamoto N; Shimomura A; Tamura K; Hamada A; Shimada T
J Pharm Biomed Anal; 2017 Oct; 145():33-39. PubMed ID: 28648785
[TBL] [Abstract][Full Text] [Related]
18. Development of Label-Free Immunoassays as Novel Solutions for the Measurement of Monoclonal Antibody Drugs and Antidrug Antibodies.
Luo YR; Chakraborty I; Lazar-Molnar E; Wu AHB; Lynch KL
Clin Chem; 2020 Oct; 66(10):1319-1328. PubMed ID: 32918468
[TBL] [Abstract][Full Text] [Related]
19. Comparisons of Serum Infliximab and Antibodies-to-Infliximab Tests Used in Inflammatory Bowel Disease Clinical Trials of Remicade®.
Marini JC; Sendecki J; Cornillie F; Popp JW; Black S; Blank M; Gils A; Van Stappen T; Hamann D; Rispens T; Thérien L; Chun K; Shankar G
AAPS J; 2017 Jan; 19(1):161-171. PubMed ID: 27600137
[TBL] [Abstract][Full Text] [Related]
20. Analysis of Glycoforms and Amino Acids in Infliximab and a Biosimilar Product Using New Method with LC/TOF-MS.
Tsuda M; Otani Y; Yonezawa A; Masui S; Ikemi Y; Denda M; Sato Y; Nakagawa S; Omura T; Imai S; Nakagawa T; Hayakari M; Matsubara K
Biol Pharm Bull; 2018 Nov; 41(11):1716-1721. PubMed ID: 30158337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
